Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Interventional Therapy for Non-Flow-Limiting Vulnerable Plaques
NCT06855537Phase 4Recruiting
- Sponsor
- Beijing An Zhen Hospital
- Start
- Nov 2025
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in coronary artery disease (CAD) and acute coronary syndrome (ACS) (2 arms), sponsored by Beijing An Zhen Hospital. Primary endpoint: Target Vessel Failure at 24 months. Started Nov 2025; status: recruiting.
02
Conditions
coronary artery disease (CAD)acute coronary syndrome (ACS)
Beyond the preview
Go deeper on NCT06855537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06855537.